glycoprotein	fexofenadine	25	23	false	none	The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	23	false	none	The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	87636
glycoprotein	fexofenadine	25	27	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  		none	87636	none	87636
glycoprotein	fexofenadine	25	27	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  		none	87636	none	87636
glycoprotein	fexofenadine	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	87636
glycoprotein	fexofenadine	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	87636
glycoprotein	fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	236474
glycoprotein	fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	236474
glycoprotein	Fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		none	87636	none	236474
fexofenadine	fexofenadine hydrochloride	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	236474
fexofenadine	fexofenadine hydrochloride	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	236474
fexofenadine	fexofenadine hydrochloride	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	2	2	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	236474
fexofenadine	fexofenadine hydrochloride	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	236474
fexofenadine	fexofenadine hydrochloride	3	2	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	236474
fexofenadine	fexofenadine hydrochloride	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	236474
fexofenadine	fexofenadine hydrochloride	7	8	false	none	Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.  12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	236474
fexofenadine	fexofenadine hydrochloride	8	8	false	none	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	236474
fexofenadine	fexofenadine hydrochloride	13	13	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	236474
fexofenadine	fexofenadine hydrochloride	13	14	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  		87636	236474
fexofenadine	fexofenadine hydrochloride	13	15	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		87636	236474
fexofenadine	fexofenadine hydrochloride	14	13	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  		87636	236474
fexofenadine	fexofenadine hydrochloride	14	14	true	positive	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  		87636	236474
fexofenadine	fexofenadine hydrochloride	14	15	true	positive	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		87636	236474
fexofenadine	fexofenadine hydrochloride	14	16	false	none	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		87636	236474
fexofenadine	fexofenadine hydrochloride	15	13	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		87636	236474
fexofenadine	fexofenadine hydrochloride	15	14	true	positive	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		87636	236474
fexofenadine	fexofenadine hydrochloride	15	15	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		87636	236474
fexofenadine	fexofenadine hydrochloride	15	17	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	15	16	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		87636	236474
fexofenadine	fexofenadine hydrochloride	17	15	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	17	17	true	positive	12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	17	16	false	none	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	17	18	true	negative	12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		87636	236474
fexofenadine	fexofenadine hydrochloride	16	14	false	none	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		87636	236474
fexofenadine	fexofenadine hydrochloride	16	15	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		87636	236474
fexofenadine	fexofenadine hydrochloride	16	17	false	none	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	16	16	false	none	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		87636	236474
fexofenadine	fexofenadine hydrochloride	16	18	true	negative	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		87636	236474
fexofenadine	fexofenadine hydrochloride	18	17	true	negative	12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		87636	236474
fexofenadine	fexofenadine hydrochloride	18	16	true	negative	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		87636	236474
fexofenadine	fexofenadine hydrochloride	18	18	false	none	Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		87636	236474
fexofenadine	fexofenadine hydrochloride	23	22	false	none	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  		87636	236474
fexofenadine	fexofenadine hydrochloride	23	25	true	positive	The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		87636	236474
fexofenadine	fexofenadine hydrochloride	23	24	true	positive	The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		87636	236474
fexofenadine	fexofenadine hydrochloride	22	22	false	none	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  		87636	236474
fexofenadine	fexofenadine hydrochloride	22	24	true	negative	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		87636	236474
fexofenadine	fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		87636	236474
fexofenadine	fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		87636	236474
fexofenadine	fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		87636	236474
fexofenadine	fexofenadine hydrochloride	24	22	true	negative	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		87636	236474
fexofenadine	fexofenadine hydrochloride	24	25	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		87636	236474
fexofenadine	fexofenadine hydrochloride	24	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		87636	236474
fexofenadine	fexofenadine hydrochloride	24	26	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		87636	236474
fexofenadine	fexofenadine hydrochloride	27	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	27	26	true	positive	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	27	29	true	positive	Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		87636	236474
fexofenadine	fexofenadine hydrochloride	27	28	true	positive	Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		87636	236474
fexofenadine	fexofenadine hydrochloride	26	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		87636	236474
fexofenadine	fexofenadine hydrochloride	26	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		87636	236474
fexofenadine	fexofenadine hydrochloride	26	26	false	none	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		87636	236474
fexofenadine	fexofenadine hydrochloride	26	28	true	positive	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		87636	236474
fexofenadine	fexofenadine hydrochloride	29	29	false	none	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		87636	236474
fexofenadine	fexofenadine hydrochloride	29	28	true	positive	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		87636	236474
fexofenadine	fexofenadine hydrochloride	29	30	false	none	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		87636	236474
fexofenadine	fexofenadine hydrochloride	28	26	true	positive	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		87636	236474
fexofenadine	fexofenadine hydrochloride	28	29	true	positive	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		87636	236474
fexofenadine	fexofenadine hydrochloride	28	28	true	positive	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		87636	236474
fexofenadine	fexofenadine hydrochloride	28	30	false	none	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		87636	236474
fexofenadine	fexofenadine hydrochloride	31	29	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	31	30	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	30	29	false	none	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		87636	236474
fexofenadine	fexofenadine hydrochloride	30	28	false	none	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		87636	236474
fexofenadine	fexofenadine hydrochloride	30	30	false	none	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		87636	236474
fexofenadine	fexofenadine hydrochloride	34	35	false	none	For pediatric patients with decreased renal function, the recommended starting dose of fexofenadine is 30 mg once daily for patients 2 to 11 years of age and 15 mg once daily for patients 6 months to less than 2 years of age.  Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	35	35	true	negative	Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	39	40	false	none	The individual apparent oral clearance estimates of fexofenadine were on average 44% and 36% lower in pediatric subjects 6 to 12 years (n = 14) and 2 to 5 years of age (n = 21), respectively, compared to adult subjects.  Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  		87636	236474
fexofenadine	fexofenadine hydrochloride	39	41	false	none	The individual apparent oral clearance estimates of fexofenadine were on average 44% and 36% lower in pediatric subjects 6 to 12 years (n = 14) and 2 to 5 years of age (n = 21), respectively, compared to adult subjects.  Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		87636	236474
fexofenadine	fexofenadine hydrochloride	36	35	true	positive	Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.  Geriatric Subjects    In older subjects (≥65 years old), peak plasma levels of fexofenadine were 99% greater than those observed in younger subjects (<65 years old).  		87636	236474
fexofenadine	fexofenadine hydrochloride	37	35	true	positive	Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.  Geriatric Subjects    In older subjects (≥65 years old), peak plasma levels of fexofenadine were 99% greater than those observed in younger subjects (<65 years old).  Mean fexofenadine elimination half-lives were similar to those observed in younger subjects.  		87636	236474
fexofenadine	fexofenadine hydrochloride	40	40	false	none	Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  		87636	236474
fexofenadine	fexofenadine hydrochloride	40	41	false	none	Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		87636	236474
fexofenadine	fexofenadine hydrochloride	41	40	false	none	Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		87636	236474
fexofenadine	fexofenadine hydrochloride	41	41	false	none	Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	2	2	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	3	2	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	7	8	false	none	Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.  12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	8	8	false	none	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	13	13	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	13	14	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	13	15	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	14	13	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	14	14	true	positive	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	14	15	true	positive	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	14	16	false	none	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	15	13	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	15	14	true	positive	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	15	15	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	15	17	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	15	16	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	17	15	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	17	17	true	positive	12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	17	16	false	none	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	17	18	true	negative	12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	16	14	false	none	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	16	15	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	16	17	false	none	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	16	16	false	none	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	16	18	true	negative	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	18	17	true	negative	12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	18	16	true	negative	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	18	18	false	none	Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	23	22	false	none	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	23	25	true	positive	The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	23	24	true	positive	The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	22	22	false	none	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  		87636	236474
fexofenadine	Fexofenadine hydrochloride	22	24	true	negative	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	24	22	true	negative	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	24	25	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	24	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	24	26	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	27	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	27	26	true	positive	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	27	29	true	positive	Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	27	28	true	positive	Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	26	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	26	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	26	26	false	none	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	26	28	true	positive	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	29	29	false	none	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	29	28	true	positive	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	29	30	false	none	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	28	26	true	positive	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	28	29	true	positive	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	28	28	true	positive	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	28	30	false	none	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	31	29	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	31	30	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	30	29	false	none	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	30	28	false	none	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	30	30	false	none	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	34	35	false	none	For pediatric patients with decreased renal function, the recommended starting dose of fexofenadine is 30 mg once daily for patients 2 to 11 years of age and 15 mg once daily for patients 6 months to less than 2 years of age.  Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	35	35	true	negative	Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	39	40	false	none	The individual apparent oral clearance estimates of fexofenadine were on average 44% and 36% lower in pediatric subjects 6 to 12 years (n = 14) and 2 to 5 years of age (n = 21), respectively, compared to adult subjects.  Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	39	41	false	none	The individual apparent oral clearance estimates of fexofenadine were on average 44% and 36% lower in pediatric subjects 6 to 12 years (n = 14) and 2 to 5 years of age (n = 21), respectively, compared to adult subjects.  Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	36	35	true	positive	Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.  Geriatric Subjects    In older subjects (≥65 years old), peak plasma levels of fexofenadine were 99% greater than those observed in younger subjects (<65 years old).  		87636	236474
fexofenadine	Fexofenadine hydrochloride	37	35	true	positive	Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.  Geriatric Subjects    In older subjects (≥65 years old), peak plasma levels of fexofenadine were 99% greater than those observed in younger subjects (<65 years old).  Mean fexofenadine elimination half-lives were similar to those observed in younger subjects.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	40	40	false	none	Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	40	41	false	none	Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	41	40	false	none	Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		87636	236474
fexofenadine	Fexofenadine hydrochloride	41	41	false	none	Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		87636	236474
fexofenadine	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	87636	42330
fexofenadine	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	87636	42330
fexofenadine	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	87636	42330
fexofenadine	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	87636	42330
fexofenadine	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	87636	42330
fexofenadine	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	87636	42330
fexofenadine	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	87636	D006632
fexofenadine	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	87636	D006632
fexofenadine	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	87636	D006632
fexofenadine	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	87636	D006632
fexofenadine	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	Histamine	7	8	false	none	Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.  12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	Histamine	7	8	false	none	Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.  12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	87636	D006632
fexofenadine	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	87636	D006632
fexofenadine	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	31	32	true	positive	Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	31	32	true	positive	Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	31	31	true	positive	Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	31	31	true	positive	Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	87636	none
fexofenadine	creatinine	34	32	true	positive	Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  Based on increases in bioavailability and half-life, a dose of 60 mg once daily is recommended as the starting dose in adult patients with decreased renal function.  For pediatric patients with decreased renal function, the recommended starting dose of fexofenadine is 30 mg once daily for patients 2 to 11 years of age and 15 mg once daily for patients 6 months to less than 2 years of age.  		87636	none	87636	none
fexofenadine	creatinine	34	32	true	positive	Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  Based on increases in bioavailability and half-life, a dose of 60 mg once daily is recommended as the starting dose in adult patients with decreased renal function.  For pediatric patients with decreased renal function, the recommended starting dose of fexofenadine is 30 mg once daily for patients 2 to 11 years of age and 15 mg once daily for patients 6 months to less than 2 years of age.  		87636	none	87636	none
fexofenadine	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	87636	D006632
fexofenadine	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	87636	D006632
fexofenadine	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	87636	D006632
fexofenadine	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	87636	D006632
fexofenadine	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	87636	D006632
fexofenadine	histamine	7	8	false	none	Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.  12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	histamine	7	8	false	none	Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.  12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	87636	D006632
fexofenadine	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	87636	D006632
fexofenadine	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	87636	D006632
fexofenadine hydrochloride	Fexofenadine hydrochloride	35	35	true	negative	Hepatically Impaired    The pharmacokinetics of fexofenadine hydrochloride in subjects with hepatic impairment did not differ substantially from that observed in healthy subjects.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	1	2	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	2	2	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	3	2	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	8	8	false	none	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	40	40	false	none	Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	40	41	false	none	Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	41	40	false	none	Administration of a 15 mg dose of fexofenadine hydrochloride to pediatric subjects 6 months to less than 2 years of age and a 30 mg dose to pediatric subjects 2 to 11 years of age produced exposures comparable to those seen with a dose of 60 mg administered to adults.  Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	41	41	false	none	Effect of Gender    Across several trials, no clinically significant gender-related differences were observed in the pharmacokinetics of fexofenadine hydrochloride.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	13	13	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	13	14	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	13	15	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	14	13	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	14	14	true	positive	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	14	15	true	positive	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	14	16	false	none	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	15	13	false	none	No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	15	14	true	positive	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	15	15	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	15	17	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	15	16	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	17	15	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	17	17	true	positive	12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	17	16	false	none	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	17	18	true	negative	12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	16	14	false	none	Pediatric subjects from two placebo-controlled trials (n = 855) treated with up to 60 mg fexofenadine hydrochloride twice daily demonstrated no significant treatment- or dose-related increases in QTc.  In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	16	15	true	positive	In addition, no statistically significant increase in mean QTc interval compared to placebo was observed in 40 healthy adult subjects given fexofenadine hydrochloride as an oral solution at doses up to 400 mg twice daily for 6 days, or in 230 healthy adult subjects given fexofenadine hydrochloride 240 mg once daily for one year.  In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	16	17	false	none	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	16	16	false	none	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	16	18	true	negative	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	18	17	true	negative	12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	18	16	true	negative	In subjects with chronic idiopathic urticaria, there were no clinically relevant differences for any ECG intervals, including QTc, between those treated with fexofenadine hydrochloride 180 mg once daily (n = 163) and those treated with placebo (n = 91) for 4 weeks.  12.3 Pharmacokinetics    The pharmacokinetics of fexofenadine hydrochloride in subjects with seasonal allergic rhinitis and subjects with chronic urticaria were similar to those in healthy subjects.  Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	18	18	false	none	Absorption    Fexofenadine hydrochloride tablets    Fexofenadine hydrochloride was absorbed following oral administration of a single dose of two 60 mg capsules to healthy male subjects with a mean time to maximum plasma concentration occurring at 2.6 hours post-dose.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	22	22	false	none	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	22	24	true	negative	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	25	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	25	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	25	26	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	24	22	true	negative	Fexofenadine hydrochloride pharmacokinetics are linear for oral doses up to a total daily dose of 240 mg (120 mg twice daily).  The administration of the 60 mg capsule contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults.  Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	24	25	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	24	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	24	26	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	26	25	true	positive	Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	26	24	true	positive	Coadministration of 180 mg fexofenadine hydrochloride tablet with a high fat meal decreased the mean area under the curve (AUC) and (Cmax) of fexofenadine by 21% and 20% respectively.  Distribution    Fexofenadine hydrochloride is 60% to 70% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.  Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	26	26	false	none	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	26	28	true	positive	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	29	29	false	none	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	29	28	true	positive	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	29	30	false	none	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	28	26	true	positive	Metabolism    Approximately 5% of the total dose of fexofenadine hydrochloride was eliminated by hepatic metabolism.  Elimination    The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy adult subjects.  Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	28	29	true	positive	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	28	28	true	positive	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	28	30	false	none	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	30	29	false	none	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	30	28	false	none	Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively.  Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		236474	236474
fexofenadine hydrochloride	Fexofenadine hydrochloride	30	30	false	none	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  		236474	236474
fexofenadine hydrochloride	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	236474	42330
fexofenadine hydrochloride	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	236474	42330
fexofenadine hydrochloride	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	236474	42330
fexofenadine hydrochloride	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	236474	42330
fexofenadine hydrochloride	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	236474	42330
fexofenadine hydrochloride	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	236474	42330
fexofenadine hydrochloride	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
fexofenadine hydrochloride	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
fexofenadine hydrochloride	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
fexofenadine hydrochloride	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
fexofenadine hydrochloride	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	236474	42330
Fexofenadine hydrochloride	terfenadine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	42330	236474	42330
Fexofenadine hydrochloride	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	236474	42330
Fexofenadine hydrochloride	terfenadine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	42330	236474	42330
Fexofenadine hydrochloride	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	236474	42330
Fexofenadine hydrochloride	terfenadine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	42330	236474	42330
Fexofenadine hydrochloride	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	Histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	creatinine	29	31	true	positive	Because the absolute bioavailability of fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or is the result of biliary excretion.  Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	creatinine	30	32	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  Peak plasma concentrations in subjects on dialysis (creatinine clearance ≤10 mL/min) were 82% greater and half-life was 31% longer than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	creatinine	30	31	true	positive	Special Populations    Pharmacokinetics in renally and hepatically impaired subjects and geriatric subjects, obtained after a single dose of 80 mg fexofenadine hydrochloride, were compared to those from healthy subjects in a separate study of similar design.  Renally Impaired    In subjects with mild to moderate (creatinine clearance 41 to 80 mL/min) and severe (creatinine clearance 11 to 40 mL/min) renal impairment, peak plasma concentrations of fexofenadine were 87% and 111% greater, respectively, and mean elimination half-lives were 59% and 72% longer, respectively, than observed in healthy subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	2	3	false	none	Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
Fexofenadine hydrochloride	histamine	13	11	true	positive	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  Greater than 49% inhibition of wheal area, and 74% inhibition of flare area were maintained for 8 hours following the 30 mg and 60 mg dose.  No statistically significant increase in mean QTc interval compared to placebo was observed in 714 adult subjects with seasonal allergic rhinitis given fexofenadine hydrochloride capsules in doses of 60 mg to 240 mg twice daily for 2 weeks.  		87636	5333	236474	D006632
terfenadine	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		42330	5333	42330	D006632
terfenadine	Histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		42330	5333	42330	D006632
terfenadine	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		42330	5333	42330	D006632
terfenadine	Histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		42330	5333	42330	D006632
terfenadine	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		42330	5333	42330	D006632
terfenadine	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		42330	5333	42330	D006632
terfenadine	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		42330	5333	42330	D006632
terfenadine	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		42330	5333	42330	D006632
Histamine	histamine	1	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  		D006632	D006632
Histamine	histamine	1	3	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		D006632	D006632
Histamine	histamine	3	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective H1-receptor antagonist activity.  Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.  Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		D006632	D006632
Histamine	histamine	3	3	false	none	Fexofenadine hydrochloride inhibited antigen-induced bronchospasm in sensitized guinea pigs and histamine release from peritoneal mast cells in rats.  		D006632	D006632
Histamine	histamine	8	8	true	positive	12.2 Pharmacodynamics    Wheal and Flare    Human histamine skin wheal and flare studies in adults following single and twice daily doses of 20 mg and 40 mg fexofenadine hydrochloride demonstrated that the drug exhibits an antihistamine effect by one hour, achieves maximum effect at 2 to 3 hours, and an effect is still seen at 12 hours.  		D006632	D006632
Histamine	histamine	11	11	false	none	Histamine skin wheal and flare studies in 7 to 12 year old subjects showed that following a single dose of 30 mg or 60 mg, antihistamine effect was observed at one hour and reached a maximum by 3 hours.  		D006632	D006632
